Among the substitute GLP-1 receptor agonists are: Albiglutide (Tanzeum) Exenatide (Bydureon, Byetta) Dulaglutide (Trulicity) Liraglutide (Saxenda, Victoza) These medications offer a range of options for individuals seeking alternatives to semaglutide, ensuring flexibility in obesity and diabetes management based on personal preferences and healthcare provider recommendations
Griffioen KJ, Wan R, Okun E, Wang X, Lovett-Barr MR, Li Y, Mughal MR, Mendelowitz D, Mattson MP
and Hurtado, M.D
Though the panels decision is a green flag for the peptide industry, there remain a number of regulatory steps before the peptides it approved can be taken to market for legal human consumption
USA 106 , 22002205 (2009)
[PMID: 35370999] PubMed record related to this compound for laboratory literature review